Mario M.-C. Kuo

Mario M.-C. Kuo has worked in the biotechnology and pharmaceutical industry since 2005. Their most recent role is Senior Principal Scientist of Protein Science at Adcentrx Therapeutics, where they are responsible for participating in the Protein Science Group to establish bioassays for lead selection and quantifying antibody and antibody-drug conjugates in animal serum samples by ELISA for PK analysis. Prior to this, they were a Principal Scientist of Protein Science at BioLegend, where they developed protocols of binding kinetics and epitipe binning using a Gator BLI system. From 2014 to 2019, they worked as a Senior Research Scientist at Polaris Pharmaceuticals, where they characterized ASS1 biomarker levels in 42 cancer cell lines by western blot. From 2009 to 2014, they were a Principal Research Scientist at the Joint Center for Biosciences, where they led a translational research project to discover clinical indications for native and engineered human cytokines. Mario M.-C. began their career in 2005 as a Postdoctoral Fellow at the Salk Institute for Biological Studies, where they expressed, purified, and characterized the RCK domain of the MthK potassium channel from E. coli.

Mario M.-C. Kuo obtained a Bachelor of Science in Chemistry from National Cheng Kung University in 1995, and a PhD in Cellular and Molecular Biology from the University of Wisconsin-Madison in 2005.